Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.33 +0.78 (+3.62%)

Streaming Delayed Price Updated: 1:31 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

33 34 Next >

Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 21, 2024

Via Benzinga

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty ↗

June 21, 2024

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.

Via Benzinga

Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday? ↗

June 21, 2024

Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple witching” day, with over $5.1 trillion of notional options exposure...

Via Benzinga

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts ↗

June 14, 2024

Via Benzinga

Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says ↗

June 21, 2024

FDA approves Sarepta's Elevidys for Duchenne muscular dystrophy patients with confirmed DMD gene mutation, aged 4+. Expanded label boosts revenue prospects for SRPT as payers and analysts show strong...

Via Benzinga

Gold Down 1%; CarMax Shares Gain After Q1 Earnings ↗

June 21, 2024

Via Benzinga

Sarepta Therapeutics Stock Soars on FDA Approval

June 21, 2024

Sarepta Therapeutics' expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market.

Via MarketBeat

Why Is Ascent Solar (ASTI) Stock Up 11% Today? ↗

June 21, 2024

Ascent Solar stock is up on Friday with heavy trading of ASTI shares after the company announced a debt payoff to institutional investors.

Via InvestorPlace

Why Is 36Kr (KRKR) Stock Up 17% Today? ↗

June 21, 2024

36Kr stock is up Friday after the content creation company announced a partnership with SenseTime that brings heavy trading of KRKR shares.

Via InvestorPlace

Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday ↗

June 21, 2024

Via Benzinga

Stock Market Weekly Review: Nvidia, AI Chip Plays Hit Resistance ↗

June 21, 2024

The Nasdaq and S&P 500 backed off highs. The Dow regained a key level.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

Pre-Market Movers - June 21, 2024 ↗

June 21, 2024

Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers.

Via Talk Markets

Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost ↗

June 21, 2024

How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging.

Via InvestorPlace

Apple To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday ↗

June 21, 2024

Via Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ↗

June 21, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 21, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

June 21, 2024

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Wall Street Looks Set For Modestly Lower Start Ahead Of Key Data, Tech Stocks Muted In Premarket: Analyst Says 'Bearish Sentiment Has Become Understandably Quiet' ↗

June 21, 2024

Wall Street is on track for a lackluster open after the S&P 500’s back-to-back record performances in the first two sessions of the week. The major index futures were all uniformly lower in early...

Via Benzinga

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy ↗

June 20, 2024

The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.

Via Investor's Business Daily

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

June 20, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

June 19, 2024

Via Benzinga

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗

June 13, 2024

Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.

Via Investor's Business Daily

Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate ↗

June 06, 2024

These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside

Via InvestorPlace

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 31, 2024

Via Benzinga

Why Sarepta Therapeutics Stock Is Rising Today ↗

May 30, 2024

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.

Via Benzinga

Topics Stocks

Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months ↗

May 28, 2024

RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 24, 2024

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.